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lipoproteins with omega-3 fatty acids: lack of an
interaction with apolipoprotein E genotype?
Valérie Conway1, Marie-Julie Allard1, Anne-Marie Minihane2,3, Kim G Jackson2, Julie A Lovegrove2
and Mélanie Plourde1*Abstract
Background: We have previously demonstrated that carrying the apolipoprotein (apo) E epsilon 4 (E4+) genotype
disrupts omega-3 fatty acids (n − 3 PUFA) metabolism. Here we hypothesise that the postprandial clearance of n − 3
PUFA from the circulation is faster in E4+ compared to non-carriers (E4−). The objective of the study was to investigate
the fasted and postprandial fatty acid (FA) profile of triacylglycerol-rich lipoprotein (TRL) fractions: Sf >400 (predominately
chylomicron CM), Sf 60 − 400 (VLDL1), and Sf 20 − 60 (VLDL2) according to APOE genotype.
Methods: Postprandial TRL fractions were obtained in 11 E4+ (ε3/ε4) and 12 E4− (ε3/ε3) male from the SATgenε study
following high saturated fat diet + 3.45 g/d of docosahexaenoic acid (DHA) for 8-wk. Blood samples were taken at fasting
and 5-h after consuming a test-meal representative of the dietary intervention. FA were characterized by gas
chromatography.
Results: At fasting, there was a 2-fold higher ratio of eicosapentaenoic acid (EPA) to arachidonic acid (P = 0.046) as well
as a trend towards higher relative% of EPA (P = 0.063) in the Sf >400 fraction of E4+. Total n − 3 PUFA in the Sf 60 − 400
and Sf 20 − 60 fractions were not APOE genotype dependant. At 5 h, there was a trend towards a time × genotype
interaction (P = 0.081) for EPA in the Sf >400 fraction. When sub-groups were form based on the level of EPA at baseline
within the Sf >400 fraction, postprandial EPA (%) was significantly reduced only in the high-EPA group. EPA at baseline
significantly predicted the postprandial response in EPA only in E4+ subjects (R2 = 0.816).
Conclusion: Despite the DHA supplement contain very low levels of EPA, E4+ subjects with high EPA at fasting
potentially have disrupted postprandial n − 3 PUFA metabolism after receiving a high-dose of DHA.
Trial registration: Registered at clinicaltrials.gov/show/NCT01544855.
Keywords: APOE4 carriers, Chylomicrons, n − 3 PUFA metabolism, VLDL, Fish-oil supplementation, Postprandial lipemiaBackground
A higher intake of fish-oil containing long chain n − 3
polyunsaturated fatty acids (n − 3 PUFA) is known to de-
crease the risks of cardiovascular disease (CVD) [1] and
potentially cognitive decline in the elderly [2]. However,
carriers of the apolipoprotein (apo) E ε4 allele (E4+), the
most important genetic risk factor for Alzheimer’s disease
(AD) [3], do not seem to be protected against cognitive* Correspondence: melanie.plourde2@usherbrooke.ca
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unless otherwise stated.decline through fish consumption [4]. In humans, three
principal isoforms of APOE (i.e. APOE2, APOE3 and
APOE4) resulting from six genotypes (i.e. ε2/ε2, ε2/ε3, ε2/
ε4, ε3/ε3, ε3/ε4 and ε4/ε4) have been identified [5]. Even if
results are still inconsistants, most studies aiming to inves-
tigate the response to fish-oil supplementation according
to APOE genotype suggested greater lipid responsiveness
in E4+ carriers compared to non-carriers (E4−).
ApoE is found on the surface of chylomicron remnants,
VLDL and HDL2 particles where it acts as a ligand for low
density lipoprotein receptor family (LDLR), thus playing
an important role in the regulation and transport of ex-
ogenous (i.e. dietary lipids) and endogenous (i.e. derivedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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meal, plasma triacylglycerol (TG) levels are temporarily
raised through hepatic (i.e. from VLDL) as well as in-
testinally derived lipids (i.e. from chylomicron particles)
[7]. This normal transitory rise in blood TG is referred
to as postprandial lipemia. In literature, APOE genotype
has been proposed as an important genetic determinant
of the interindividual variability in postprandial lipemia
[8,9]. The differencial affinity of APOE isoform for its
clearence receptors, the preferential incorporation of
apoE4 within TG-rich lipoproteins (TRL), and its modu-
lating action on size and lipid composition of plasma TRL
may all explain part of the APOE genotype-induce vari-
ability in lipid metabolism [6,10].
Recently, Liang et al. [11] reported that APOE genotype
was not significantly associated to differencial modifica-
tion in levels of DHA and EPA within TC, TG or LDL-C,
but was significantly associated to their concentrations
with HDL-C. Supporting differential lipid metabolism be-
tween E4+ and E4− subjects, our previous results have
demonstrated that postprandial β-oxidation of DHA was
higher in E4+ and that increment of plasma level of DHA
following fish-oil supplementation was reduced in this
population [12,13]. Studying the metabolism of n − 3
PUFA in E4+, by understanding how n − 3 PUFA are
transported in TRL, could help establish effective n − 3
PUFA dosage and duration for disease prevention in E4+
patient.
Our hypothesis is that the clearance of n − 3 PUFA is
faster in E4+ subjects, resulting in lower% of circulating
n − 3 PUFA in postprandial TRL after acute DHA intake.
This study is a secondary analysis looking at the re-
sponses to an 8-wk diet high in fat and saturated fat sup-
plemented with 3.45 g/d of DHA (HSF-DHA diet) andTable 1 Baseline anthropometric and biochemical data for ca
following the 8-wk HSF-DHA diet
Anthropometric Whole group (N = 23)
Age (y) 54 ± 2
BMI (kg/m2) 25.97 ± 0.57
Biochemical
Total cholesterol (mmol/L) 5.67 ± 0.13
HDL-C (mmol/L) 1.45 ± 0.06
LDL-C (mmol/L) 4.04 ± 0.16
TG (mmol/L) 1.07 ± 0.09
NEFA (μmol/L) 378.1 ± 27.3
ApoE (μg/mL) 37.33 ± 2.27
Glucose (mmol/L) 5.68 ± 0.08
CRP (μg/mL) 1.28 ± 0.31
Values are presented as mean ± SEM. P values were obtained using one-way ANOV
indicate significant effects (P < 0.05).
ApoE: Apolipoprotein E; BMI: Body mass index; CRP: C-reactive protein; HDL-C: High-
NEFA: Non-esterified fatty acids; TG: Triacylglycerol.to the postprandial response to a macronutrient match-
ing HSF-DHA test-meal according to APOE genotype.
Therefore, our objective was to determine the FA profile
in different TRL (Svedberg flotation rate: Sf >400 (pre-
dominately chylomicrons), Sf 60 − 400 (very low density
lipoprotein 1; VLDL1) and Sf 20 − 60 (VLDL2)) isolated
at fasting (0 h) and 5-h after eating a high-fat test-meal
containing DHA (3.45 g) in E4+ and E4− men.
Results
Participants
The characteristics of the E4− and E4+ participants
matched for age and BMI are shown in Table 1. There
was no difference in plasma lipids or glucose levels be-
tween the two genotype groups following the 8-wk
HSF-DHA diet − referred as baseline. The plasma con-
centration of apoE differs significantly between E4−
and E4+ participants since E4+ had 28% less plasma
apoE (μg/mL) when compared to non-carriers after the
8-wk HSF-DHA diet. The test-meal was well tolerated
by all participants. Only one of the recruited subjects
(from the E4+ group) dropped the study protocol.
Fatty acid profile of TRL
The fatty acid profile was performed after the partici-
pants received the HSF-DHA diet for 8 weeks. Overall,
there was limited APOE genotype effect on fasting and
postprandial FA profile of the TRL fractions (Figure 1A
and B).
Sf >400 fraction
Following the 8-wk DHA enriched diet, the relative% of
fasting DHA in Sf >400 fraction significantly predicted
the level of plasma TG, independently of APOE genotyperriers (E4+) and non-carriers (E4−) of an APOE4 allele
E4− (N = 12) E4+ (N = 11) P genotype
52 ± 2 56 ± 3 0.346
26.53 ± 0.72 25.36 ± 0.91 0.319
5.77 ± 0.22 5.57 ± 0.16 0.478
1.48 ± 0.08 1.42 ± 0.11 0.649
4.13 ± 0.26 3.96 ± 0.20 0.615
1.03 ± 0.12 1.11 ± 0.15 0.681
379.1 ± 33.6 377.0 ± 45.6 0.970
41.69 ± 3.51 32.58 ± 2.14 0.042
5.58 ± 0.10 5.78 ± 0.11 0.205
1.07 ± 0.29 1.50 ± 0.57 0.501
A in SPSS version 22.0 (IBM Corp., Armonk, NY). Bold characters are used to
density lipoprotein-cholesterol; LDL-C: Low-density lipoprotein-cholesterol;
Sf >400 fraction
Sf 60-400 fraction
Sf 20-60 fraction
A B
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Figure 1 Fatty acid profile of TRL (top figures, Sf >400; middle figures, Sf 400 − 60; bottom figures, Sf 20 − 60) in E4− (■) and E4+ (□) at
A) fasting and B) in postprandial. ANOVA was used to investigate the presence of significant difference according to time and according to
APOE genotype for the relative% of saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), omega-3 and omega-6 fatty acids (n − 3
PUFA and n − 6 PUFA). ✝ Trend effect for genotype (P = 0.084).
Conway et al. Lipids in Health and Disease 2014, 13:148 Page 3 of 9
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towards higher relative% of EPA and n‒3 PUFA at fast-
ing in E4+ subjects compared to E4− (P = 0.084,
Figure 1A), all other FA did not differ according to
APOE genotype (Table 2). The ratio of EPA to ara-
chidonic acid (AA, 20:4 n − 6) was >2-fold higher in
Sf >400 fraction of E4+ subjects compared E4− with
respective values of 2.4 ± 0.8 vs. 1.1 ± 0.5 (P = 0.046,
data not shown). At fasting, 16:0 (34%), 18:0 (24 − 27%)
and 18:1 n − 9 (22%) were the main FA whereas alpha-
linoleic acid (ALA, 18:3 n − 3) composed 47% of totaln − 3 PUFA (Table 2). There was a significant correlation
between the relative% of DHA at fasting and the concen-
tration of triacylglycerol (TG), non-esterified FA (NEFA),
small and dense LDL-C and C-reactive protein (CRP)
concentrations within the Sf >400 fraction. Similarly,
the relative% of 18:2 n − 6 at fasting was correlated to
the concentration of small and dense LDL-C (r = 0.615,
P = 0.025, data not shown).
Five hours after receiving the test meal, none of the
tested FA in the Sf >400 fraction were APOE genotype-
dependant (Table 2). There was no significant time ×
Table 2 Fatty acid profiles of Sf >400 fractions in response to acute docosahexaenoic acid (DHA) intake in carriers
(E4+) and non-carriers (E4−) of an APOE4 allele
Fasting Postprandial Change P values
(relative%) (relative%) (Δ) Interaction Genotype Time
16:0 E4+ 33.44 ± 2.05 33.75 ± 0.77 + 0.31 0.457 0.833 0.487
E4− 34.26 ± 1.49 33.76 ± 1.01 + 0.50
18:0 E4+ 23.75 ± 2.92 10.61 ± 1.65 − 13.14 0.482 0.310 <0.001
E4− 27.12 ± 1.73 9.74 ± 1.03 − 17.38
16:1 n − 7 E4+ 1.44 ± 0.18 0.44 ± 0.08 − 1.00 0.467 0.174 0.011
E4− 1.46 ± 0.13 0.74 ± 0.20 − 0.72
18:1 n − 9 E4+ 21.74 ± 4.21 33.70 ± 1.18 + 11.96 0.708 0.969 <0.001
E4− 22.51 ± 1.54 33.12 ± 0.72 − 10.61
18:2 n − 6 E4+ 8.63 ± 2.90 12.51 ± 0.68 + 3.88 0.219 0.520 0.001
E4− 5.69 ± 0.88 13.31 ± 1.05 + 7.62
20:4 n − 6 E4+ 0.78 ± 0.12 0.77 ± 0.08 − 0.01 0.547 0.265 0.757
E4− 1.44 ± 0.65 0.98 ± 0.11 − 0.46
18:3 n − 3 E4+ 2.68 ± 0.85 0.89 ± 0.08 − 1.79 0.196 0.309 0.015
E4− 1.60 ± 0.37 0.93 ± 0.07 − 0.67
20:5 n − 3 E4+ 1.52 ± 0.29 0.86 ± 0.10 − 0.66 0.081 0.251 0.154
E4− 0.90 ± 0.21 0.86 ± 0.13 − 0.04
22:6 n − 3 E4+ 1.50 ± 0.65 2.53 ± 0.48 + 1.03 0.949 0.219 0.024
E4− 0.75 ± 0.16 1.96 ± 0.45 + 1.21
Values are presented as mean relative percentages ± SEM or as change (Δ) compared to fasted state (i.e.% at postprandial value –% at fasting value). P values
were obtained using a Factorial Repeated Measures (Split-Plot) ANOVA in SPSS version 22.0 (IBM Corp., Armonk, NY). Bold characters are used to indicate
significant effects (P < 0.05).
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there was a trend towards a significant time × genotype
interaction on the relative% of EPA (P = 0.081). The rela-
tive% of EPA in postprandial was strongly correlated with
DHA (r = 0.875, P < 0.001, data not shown). Five hours
after receiving the HSF-DHA test-meal, the postprandial
relative% of SFA in the Sf >400 was significantly reduced
compared to fasting, whereas the relative% of both MUFA
and total n − 6 PUFA were increased. These time effects
were independent of APOE genotype (Figure 1B).
EPA level at fasting, had a significant impact on the
postprandial response (ΔEPA) to the test-meal (P =
0.021) Since EPA level at fasting tended to change the
postprandial response of EPA within the Sf >400 frac-
tion, two groups were formed based on the median level
of EPA at fasting in the Sf >400 fraction (low-EPA sub-
group = EPA < 1.0% vs. high-EPA sub-group = EPA >
1.0%). There was a significant interaction between fast-
ing EPA-status (i.e. low or high) and APOE genotype (P
interaction = 0.036; Figure 2). Postprandial EPA was 7-
fold lower in participants in the high-EPA sub-group
than in the low-EPA sub-group (Figure 2A). Similarly, the
postprandial response for EPA (ΔEPA) after the test-meal
was greater in E4+ subjects (Figure 2B). In multiple regres-
sion analysis, the relative% of EPA in Sf >400 lipoproteinsat fasting, significantly predicted the postprandial response
in EPA (ΔEPA) only in E4+ subjects (R2 = 0.816, P < 0.014,
data not shown).
Sf >60 − 400 fraction
At fasting, relative% of all tested FA were independent of
APOE isoforms. At fasting, the fatty acid profile of the Sf
60 − 400 fraction was mainly 16:0 (29%), SA (8 − 9%) and
18:1 n‒9 (30%). The main n − 3 PUFA was DHA (Table 3).
Five hours after the HSF-DHA test-meal, the relative%
of all tested FA were independent of the APOE genotype
(Table 3). DHA represented 59% and 62% of total n − 3
PUFA in E4− and in E4+ respectively. There was no sig-
nificant time × genotype interaction or independent
genotype effect on the postprandial FA profile of Sf 60 −
400 lipoproteins (Table 3). The relative% of 18:2 n‒6 in
postprandial was positively correlated to LDL-C and the
relative% of 18:3 n‒3 was positively correlated to HDL-C
(data not shown).
Sf 20 − 60 fraction
At fasting, relative% of all tested FA were independent of
APOE isoforms with the exception of, which was signifi-
cantly lower in E4+ compared to E4− (Table 4). At fasting,
16:0 (28%), 18:0 (9%) and 18:1 n‒9 (28 − 30%) were the
-1 .0
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Figure 2 Changes in the eicosapentaenoic acid (ΔEPA) content
of postprandial Sf >400 lipoproteins depending on: A) EPA-
status at fasting (N = 11 or 12/group); B) APOE genotype
(N = 11 or 12/group); E4− (■) and E4+ (□). Median fasting level of
EPA in Sf >400 lipoproteins was used to create the low <1.0% (●) and
high >1.0% sub-groups (○). Factorial Repeated Measures (Split-Plot)
ANOVA was used to investigate the presence of significant interaction.
P value for EPA-status at fasting × genotype interaction was = 0.036.
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% of AA at fasting was significantly correlated to plasma
concentration of apoE (r = 0.496, P = 0.019; data not
shown). In multiple regression, HDL-C concentration was
able to predict the variation of AA at fasting (%) only in
E4+ subjects (R2 = 0.492, P = 0.010; data not shown).
Five hours after the HSF-DHA test-meal, the relative%
of FA were all independent of the APOE genotype
(Table 4). There was no significant time × genotype
interaction for any of the tested FA (Table 4). The rela-
tive% of 18:3 n‒3 at fasting was positively correlated to
the postprandial level of ALA (r = 0.553, P = 0.009), EPA
(r = 0.611, P = 0.003), DHA (r = 0.479, P = 0.028) and to
plasma concentration of HDL-C (r = 0.592, P = 0.004). It
was also negatively correlated to plasma concentration
of TG (r = −0.510, P = 0.015) (data not shown).
Discussion
Contrary to our hypothesis, total n − 3 PUFA levels of
the TRL fractions after a chronic DHA supplementationfor 8-wk (3.45 g/d) was not significantly dependent on
APOE genotype. However, there was a >2-fold higher ra-
tio of EPA:AA in the Sf >400 fraction as well as a trend
towards higher levels of EPA at fasting in E4+ subjects
compared to E4‒. When groups were formed based on
fasting EPA in Sf >400 lipoproteins, the postprandial re-
sponse for EPA was greater in E4+ from the high-EPA
sub-group. EPA enrichment of lipoproteins at fasting
predicted more than 80% of the EPA-response in E4+
subjects following the prescribed DHA supplementation
for 8-wk (3.45 g/d).These results suggests that in E4+,
the response to fish-oil supplementation is dependant of
the fasting EPA-status.
The greater reduction of EPA in the Sf >400 lipopro-
teins of the E4 + from the high fasting EPA sub-group,
may potentially be explained by enhanced hepatic uptake
of large TRL. In accordance with this hypothesis, apoE4
has a greater affinity for the low density lipoprotein re-
ceptor (i.e. LDL-R), hence, enhancing its clearance from
blood. Since apoE4 preferentially incorporates into large
TLR particles [6,10], Sf >400 lipoproteins may be prefer-
entially and more rapidly cleared in E4 +.Therefore, EPA
clearance may be faster in E4 + and EPA may thereafter
be preferentially catabolized or metabolized in the liver
due to its poor incorporation into cell membranes .
Thereafter, subjects may preferentially catabolize EPA.
This hypothesis is supported by results from in vivo and
in vitro experiments in which TG-lowering action of
fish-oil supplementation was explained throughout en-
hance mitochondrial lipid catabolism (i.e. β-oxidation)
[14,15]. As explained by Olano-Martin et al. [16], reduc-
tion of TG after EPA and/or DHA supplementation is
partially attributable to up-regulation of genes involved
in FA catabolism. Recent work from our group sug-
gested that FA uptake and FA β-oxidation by the liver of
apoE-targeted replacement mice expressing human
APOE4 genotype is enhance through increase concentra-
tions of hepatic carnitine acyltransferase (CPT1), the
limiting enzyme of FA β-oxidation [17]. Moreover, FA
preference towards β-oxidation may be modify in E4+ as
suggested in a previous study [13]. The greater reduction
of EPA, with no apparent reduction in DHA, can be re-
lated to preferential catabolism of EPA over DHA, as
DHA is a much poorer substrate than EPA for the acyl-
CoA synthase [14,18]. These latter hypotheses and the
underling mechanisms are as yet speculative and need
further investigation. Even if our results seem to suggest
that the isoform-specific action of APOE genotype is
limited and mostly affects FA profile of large TRL (i.e.
Sf > 400 fraction), a complete picture of the APOE
isoform-specific modulation of n − 3 PUFA transport
and clearance by adding FA profiles of LDL and HDL
particles would have added to the present results −
these lipoproteins were not available for us to analyse.
Table 3 Fatty acid profiles of Sf 60 − 400 fractions in response to acute docosahexaenoic acid intake in carriers (E4+)
and non-carriers (E4−) of an APOE4 allele
Fasting Postprandial Change P values
(relative%) (relative%) (Δ) Interaction Genotype Time
16:0 E4+ 29.01 ± 1.35 30.21 ± 0.74 + 1.20 0.981 0.688 0.063†
E4− 28.54 ± 0.73 29.77 ± 0.73 + 1.23
18:0 E4+ 9.15 ± 1.27 5.96 ± 0.65 − 3.19 0.452 0.534 <0.001
E4− 8.07 ± 0.71 5.80 ± 0.47 − 2.27
16:1 n − 7 E4+ 3.12 ± 0.39 2.34 ± 0.36 − 0.78 0.676 0.823 <0.001
E4− 3.27 ± 0.27 2.38 ± 0.24 − 0.89
18:1 n − 9 E4+ 28.93 ± 0.12 30.29 ± 0.81 + 1.36 0.307 0.326 0.415
E4− 30.52 ± 0.52 30.36 ± 0.42 − 0.16
18:2 n − 6 E4+ 15.84 ± 0.66 17.41 ± 0.48 + 1.57 0.883 0.912 0.001
E4− 15.97 ± 0.55 17.42 ± 0.55 + 1.45
20:4 n − 6 E4+ 1.91 ± 0.17 2.05 ± 0.14 + 0.14 0.648 0.449 0.047
E4− 2.03 ± 0.16 2.25 ± 0.16 + 0.22
18:3 n − 3 E4+ 1.64 ± 0.19 1.35 ± 0.12 − 0.29 0.791 0.409 0.018
E4− 1.49 ± 0.09 1.25 ± 0.10 − 0.24
20:5 n − 3 E4+ 1.19 ± 0.13 1.25 ± 0.04 − 0.06 0.526 0.948 0.154
E4− 1.32 ± 0.30 1.15 ± 0.11 − 0.17
22:6 n − 3 E4+ 3.74 ± 0.43 4.33 ± 0.33 + 0.59 0.878 0.497 0.099
E4− 3.44 ± 0.45 3.91 ± 0.47 + 0.47
Values are presented as mean relative percentages ± SEM or as change (Δ) compared to fasted state (i.e.% at postprandial value –% at fasting value). P values
were obtained using a Factorial Repeated Measures (Split-Plot) ANOVA in SPSS version 22.0 (IBM Corp., Armonk, NY). Bold characters are used to indicate
significant effects (P < 0.05). †Trend effect was set at P < 0.09.
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sensitivity of fasting [19] and postprandial [20] TG to diet-
ary DHA intake in E4+ is usually explained throughout
isoform-specific modulation of TLR metabolism rather
than to LDL and HDL particles.
Trials investigating DHA supplementation generally re-
port a dose‒dependent increase in both plasma DHA and
EPA [21]. For example, in the 8-wk HSF-DHA diet of the
SATgenε study, there was a 2-fold increase of DHA and
EPA in plasma phospholipids in E4+ and E4‒ [22]. The
lack of APOE isoform-specific postprandial response dur-
ing acute DHA ingestion in this follow-up study could sim-
ply result from the enrichment of TRL at baseline, which
occurs whilst the HSF-DHA diet for 8-wk [22]. This en-
richment may have masked any subtle changes in the post-
prandial response between E4− and E4+ subjects. Greater
modulation of postprandial response to n − 3 PUFA sup-
plementation may be possible through intake of EPA
enriched test-meal rather than DHA enriched test-meal.
Indeed, Cazzola et al. [23] proposed based on their dose–
response investigation on normotriacylglycerolaemic males
supplemented 1.4 to 4.05 g EPA/day for 12-wk, that EPA
may be responsible for the TG-lowering action of fish oil.
These hypotheses are speculative and deserve to be tested
in future investigation according to APOE genotype.AA was lower in Sf 20 − 60 lipoproteins of E4+ at
fasting. This is an intriguing result since usually AA
rarely varies in plasma lipids. A significant reduction in
AA (‒14 μmol/L) was reported while studying postprandial
response to a 7-week supplementation with n − 3 PUFA
(1 g/d EPA and DHA) in normolipaemic individuals, with
no regards to APOE genotype [24]. Thus, the lower level of
plasma AA in fasted E4+ subjects may have result from
the greater responsiveness of E4+ [20] to the prior 8-wk
HSF-DHA diet [22]. AA kinetics has never been studied in
humans so whether APOE genotype significantly changes
its kinetics remains to be established.
This study has strengths and limitations. The main
limitations are related to the high saturated fat content
of the HSF-DHA-rich test meal (53 g of fat), to lipopro-
tein FA profile in relative% rather than in concentration,
and finally to the use of a single postprandial time-point
(5 h) for this analysis. Indeed, fat quality and quantity
[8], as well as the vehicle in which DHA is administered
[25], may all affect postprandial lipid response to acute
ingestion and thus, may mask subtle changes according
to APOE genotype. Finally, providing FA profile in con-
centrations rather than in relative% would have been in-
formative but unfortunately this analysis was not
performed and due to the limited volume of sample
Table 4 Fatty acid profiles of Sf 20 − 60 fractions in response to acute docosahexaenoic acid intake in carriers (E4+)
and non-carriers (E4−) of an APOE4 allele
Fasting Postprandial Change P values
(relative%) (relative%) (Δ,%) Interaction Genotype Time
16:0 E4+ 28.40 ± 1.07 29.71 ± 1.24 + 1.31 0.535 0.330 0.193
E4− 27.69 ± 0.75 28.61 ± 0.80 + 0.92
18:0 E4+ 8.72 ± 0.53 7.12 ± 0.86 − 1.60 0.775 0.619 0.001
E4− 9.29 ± 0.67 7.28 ± 0.46 − 2.01
16:1 n − 7 E4+ 2.49 ± 0.27 2.25 ± 0.26 − 0.24 0.630 0.921 <0.001
E4− 2.60 ± 0.20 2.26 ± 0.18 − 0.34
18:1 n − 9 E4+ 29.79 ± 0.94 29.83 ± 1.17 + 0.04 0.166 0.381 0.148
E4− 28.01 ± 0.92 29.45 ± 0.43 + 1.44
18:2 n − 6 E4+ 17.12 ± 0.85 17.69 ± 0.47 + 0.57 0.552 0.259 0.164
E4− 17.84 ± 0.55 17.96 ± 0.49 + 0.12
20:4 n − 6 E4+ 2.22 ± 0.16 2.39 ± 0.18 + 0.17 0.488 0.022 0.681
E4− 2.91 ± 0.23 2.77 ± 0.19 − 0.14
18:3 n − 3 E4+ 1.31 ± 0.16 1.19 ± 0.09 − 0.12 0.367 0.755 0.025
E4− 1.35 ± 0.12 1.07 ± 0.05 − 0.28
20:5 n − 3 E4+ 1.42 ± 0.17 1.24 ± 0.11 − 0.18 0.746 0.991 0.133
E4− 1.39 ± 0.16 1.25 ± 0.11 − 1.14
22:6 n − 3 E4+ 3.74 ± 0.53 3.77 ± 0.38 + 0.03 0.779 0.706 0.896
E4− 4.08 ± 0.46 3.82 ± 0.52 − 0.26
Values are presented as mean relative percentages ± SEM or as change (Δ) compared to fasted state (i.e.% at postprandial value –% at fasting value). P values
were obtained using a Factorial Repeated Measures (Split-Plot) ANOVA in SPSS version 22.0 (IBM Corp., Armonk, NY). Bold characters are used to indicate
significant effects (P < 0.05).
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have given complementary information regarding FA
profiles, especially with regards to the level of each TRL
according to APOE genotype. This study represents a
secondary analysis of a trial designed to investigate diet-
ary fat quality and quantity on postprandial lipid metab-
olism according to APOE genotype [22]. Since recent
evidences from another group suggest different meta-
bolic activities after EPA and DHA supplementation
[11], and considering that Cazzola et al. [23] proposed
that EPA may be more potent at reducing plasma TG
than DHA, studying the response to chronic and acute
EPA intake, on the FA profile of TRL according to APOE
genotype, and not in a context of HSF diet, would be of
great interest.
Conclusions
This study reported that FA profile of large TRL (Sf >400)
is the most modified by chronic and acute DHA intake
and that it is not APOE-isoform dependant. Despite
the prior HSF-DHA diet contained very low levels of
EPA, E4+ subjects with high fasting plasma levels of
EPA potentially have disrupted postprandial n − 3 PUFA
metabolism after receiving an acute high-dose of DHA.
In future trial design, looking at the interaction betweenparticipant’s EPA-status at baseline and APOE genotype
on the response to EPA and/or DHA supplementation
should be considered.
Methods
Participants
Twenty-three men − 12 E4− (ε3/ε3) and 11 E4+ (ε3/ε4) −
participating in the SATgenε study also undertook
postprandial studies at the end of three iso-energetic
8-wk diets: 1) low-fat diet (LF); 2) high-fat, high satu-
rated fat (HSF); 3) HSF + 3.45 g/day DHA (HSF-DHA)
diets. All participants consumed the three diets in the
same order, without in between washout period. The
present postprandial study only investigated the chronic
and acute response to HSF-DHA diet in E4− and E4 +men.
Complete details of the SATgenε dietary intervention
and of the postprandial investigation have been pre-
sented in detail elsewhere [20,22]. Briefly, twenty-four
hours prior postprandial intervention, participants were
asked to abstain from alcohol and to consume a low-fat
meal (<0 g fat) before 8 pm in the evening. The HSF-
DHA test-meal (5.4 MJ) used in this postprandial inves-
tigation matched the macronutrient composition of the
dietary intervention (i.e. HSF-DHA diet) as detailed in
[20]. Briefly HSF-DHA meal was composed of (45.1%
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saturated fatty acids, 12.2% monounsaturated fatty acids,
6.6% polyunsaturated fatty acids with 0.2% EPA and
1.4% DHA). The HSF-DHA test-meal was a warm choc-
olate drink containing the fish-oil (DHA), with toast and
jam. It was provided and consumed within 20-min. The
DHA enriched test-meal contained 5.7% saturated fatty
acids, 11.6% monounsaturated fatty acids, 82% polyun-
saturated fatty acids, 8.3% EPA, 3.1% DPA, and 57.5%
DHA, which provided 3.45 g of DHA/d + 0.19 g EPA/d
(Croda Healthcare, UK). This study was approved by the
University of Reading Research Ethics Committee and is
registered at clinicaltrials.gov as NCT01384032. The
study was conducted according to the Declaration of
Helsinki’s guidelines. Participants of the SATgenε trial
provided their informed consent for the study.Biochemical assessments
After an overnight fast, subjects attended the investigation
unit where an indwelling cannula was inserted into a fore-
arm vein. Two blood samples were taken at baseline (i.e.
fasting state) and 5-h after consuming the HSF-DHA test-
meal (i.e. providing 3.45 g of DHA). Blood samples were
transferred to heparin containing tubes and were sepa-
rated by centrifugation at 1700 × g for 10 min in a bench-
top centrifuge at 4°C, and stored at −20°C until analysis.
In order to prevent the proteolytic degradation of the apo-
lipoproteins, 6 μL EDTA (0.5 mol/L), 3 μL PMSF
(10 mmol/L in isopropanol) and 15 μL aprotinin (10 000
kallikrein inactivator units/mL) were added immediately
to the plasma. The plasma was stored overnight at 4°C
until isolation of the Sf >400 (predominantly chylo-
micron), Sf 60–400 (VLDL1) and Sf 20–60 (VLDL2) frac-
tions using density gradient ultracentrifugation, as
previously described [23]. After isolation of TRL fractions
(1 mL), recovered volumes were divided into portions and
stored at −20°C until further analysed.Fatty acid profile analyses
Total lipids were extracted from the TRL fractions
(150 μL) using the Folch method [26]. The plasma total
lipid extract was then saponified using 1 M KOH/metha-
nol and heated at 90°C for 1-h, which hydrolyses the fatty
acids from cholesterol and glycerol. After cooling to room
temperature, hexane and saline were added. The hexane
and cholesterol phase were discarded and the remaining
saline and fatty acid salt mixture was acidified with HCl
to obtain the free fatty acids. Transmethylation of the
resulting non-esterified FA into FA methyl esters was
performed using boron 14% trifluoride/methanol
(Sigma-Aldrich, Saint-Louis, MO). FA methyl esters
were analyzed using a gas chromatograph (model 6890,
Agilent, Palo Alto, CA) equipped with a 50 m BPX-70fused capillary column (SGE, Melbourne, Australia) as
described in [27].
Statistics
This study represents a secondary analysis of the SATgenε
trial conducted at the University of Reading (UK) [20].
Sample size estimation was originally performed on the ex-
pected change in postprandial TG-response between geno-
type groups (i.e. E4− vs. E4+). The sample size estimation
was performed to allow the detection of a minimum of
238 mmol/L ×min change in TG-response between geno-
type groups. A SD of 189 mmol/L × min in response to
dietary modifications has been used for sample size cal-
culations. Based on previous studies, the required num-
ber per genotype groups was N = 10 (alpha = 0.05 two-
tailed, power = 80%) [19]. The same number of subjects
(N = 10/group) was required to detect a minimum of
90 nmol/mL × h with a SD of 70 nmol/mL × h change
in [13C]-DHA metabolism between E4+ and E4− [13]
with an anticipated dropout of 15%.
All data were analysed for statistical differences using
a Factorial Repeated Measures (Split-Plot) ANOVA in
SPSS version 22.0 (IBM Corp., Armonk, NY). Normal
distribution and homogeneity of variance were evaluated
before further analysis. The main effect of APOE geno-
type on fasting and on the changes (Δ) in serum n − 3
PUFA profile was also investigated using non-parametric
analysis of variance in SPSS. The median value for EPA
relative% in the TRL fraction at baseline was used to cre-
ate groups (i.e. low-EPA group or high-EPA group). The
impact of EPA-status at baseline (i.e. Low or High) and
APOE genotype on the response (Δ) to HSF-DHA test-
meal was also investigated using factorial (two-way)
ANOVA analysis of variance in SPSS. When interaction
terms were found significant, the interaction was pre-
sented graphically. Bivariate Pearson correlation analysis
and multivariate stepwise regression models were used
to investigate associations among outcomes. Data are
presented as means ± SEMs and P values <0.05 were
considered statistically significant. Trend effect was set
at P values ≤ 0.085. Each FA is presented in relative%
compared to total-FA identified or as postprandial re-
sponse (Δ):
postprandial response Δð Þ
¼ value relative %ð Þ at 5h− values relative %ð Þ at 0h½ 
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